Table 5.
Association of MTHFR C677T, A1298C and MTR A2576G haplotypes with clinical characteristics of breast cancer patients.
| Haplotype (MTHFRC677T -MTHFRA1298C-MTR A2576G) | Age (n= 100) | OR (95% CI) | p value | |
|---|---|---|---|---|
| > 45 | <= 45 | |||
| C-A-A | 54 (31.0%) | 59 (40.4%) | 1.00 (Reference) | |
| C-A-G | 2 (1.1%) | 13 (8.9%) | 0.168 (0.036 - 0.779) | 0.011 |
| C-C-A | 32 (18.4%) | 22 (15.1%) | 1.589 (0.824 - 3.064) | 0.165 |
| C-C-G | 7 (4.0%) | 2 (1.4%) | 3.824 (0.761 - 19.212) | 0.083 |
| T-A-A | 9 (5.2%) | 5 (3.4%) | 1.967 (0.620 - 6.235) | 0.244 |
| T-A-G | 8 (4.6%) | 3 (2.1%) | 2.914 (0.735 - 11.550) | 0.114 |
| T-C-A | 11 (6.3%) | 10 (6.8%) | 1.202 (0.473 - 3.054) | 0.699 |
| T-C-G | 51 (29.3%) | 32 (21.9%) | 1.741 (0.979 - 3.097) | 0.058 |
| Tumor Size(n= 100) | ||||
| T2 - T4 | T1 | |||
| C-A-A | 30 (18.5%) | 11 (28.9%) | 1.00 (Reference) | |
| C-A-G | 2 (1.2%) | 7 (18.4%) | 0.105 (0.019 - 0.583) | 0.004 |
| C-C-A | 22 (13.6%) | 12 (31.6%) | 0.672 (0.251 - 1.802) | 0.429 |
| C-C-G | 7 (4.3%) | 0 (0.0%) | 1.367 (1.135 - 1.645) | 0.119 |
| T-A-A | 5 (3.1%) | 2 (5.3%) | 0.917 (0.155 - 5.432) | 0.924 |
| T-A-G | 7 (4.3%) | 1 (2.6%) | 2.567 (0.283 - 23.309) | 0.389 |
| T-C-A | 11 (6.8%) | 1 (2.6%) | 4.033 (0.465 - 34.993) | 0.178 |
| T-C-G | 78 (48.1%) | 4 (10.5%) | 7.150 (2.112 - 24.203) | 0.001 ** |
| Lymph nodes (n= 100) | ||||
| N1 - N3 | N0 | |||
| C-A-A | 23 (17.4%) | 11 (28.9%)18 (26.5%) | 1.00 (Reference) | |
| C-A-G | 2 (1.5%) | 7 (10.3%) | 0.224 (0.041 - 1.210) | 0.066 |
| C-C-A | 15 (11.4%) | 19 (27.9%) | 0.618 (0.247 - 1.544) | 0.302 |
| C-C-G | 5 (3.8%) | 2 (2.9%) | 1.957 (0.339 - 11.281) | 0.447 |
| T-A-A | 3 (2.3%) | 4 (5.9%) | 0.587 (0.116 - 2.963) | 0.516 |
| T-A-G | 7 (5.3%) | 1 (1.5%) | 5.478 (0.617 - 48.666) | 0.095 |
| T-C-A | 10 (7.6%) | 2 (2.9%) | 3.913 (0.760 - 20.146) | 0.087 |
| T-C-G | 67 (50.8%) | 15 (22.1%) | 3.496 (1.520 - 8.041) | 0.003** |
| Stage (n= 100) | ||||
| III - IV | ||||
| C-A-A | 15 (13.2%) | 26 (30.2%) | 1.00 (Reference) | |
| C-A-G | 2 (1.8%) | 7 (8.1%) | 0.495 (0.091 - 2.698) | 0.410 |
| C-C-A | 13 (11.4%) | 21 (24.4%) | 1.073 (0.419 - 2.745) | 0.883 |
| C-C-G | 6 (5.3%) | 1 (1.2%) | 10.400 (1.141 - 94.835) | 0.015* |
| T-A-A | 3 (2.6%) | 4 (4.7%) | 1.300 (0.256 - 6.610) | 0.751 |
| T-A-G | 7 (6.1%) | 1 (1.2%) | 12.133 (1.359 - 108.364) | 0.008** |
| T-C-A | 9 (7.9%) | 3 (3.5%) | 5.200 (1.216 - 22.234) | 0.019 |
| T-C-G | 59 (51.8%) | 23 (26.7%) | 4.446 (2.003 - 9.871) | 0.001** |
| Breast Subtypes (n=100) | ||||
| Her2 Enriched | ||||
| C-A-A | 12(12.2%) | 21(33.9%) | 1.00 (Reference) | |
| C-A-G | 2(2.0%) | 6(9.7%) | 0.583(0.101-3.358) | 0.546 |
| C-C-A | 12(12.2%) | 16(25.8%) | 1.312(0.468-3.681) | 0.605 |
| C-C-G | 5(5.1%) | 0(0.0%) | 18.920 (0.963-371.679) | 0.053 |
| T-A-A | 3(3.1%) | 3(4.8%) | 1.750(0.304-10.075) | 0.531 |
| T-A-G | 5(5.1%) | 2(3.2%) | 4.375(0.733-26.116) | 0.105 |
| T-C-A | 8(8.2%) | 2(3.2%) | 7.000(1.274-38.475) | 0.025 |
| T-C-G | 51(52.0%) | 12(19.4%) | 7.437(2.882-19.191) | <0.001** |
OR: odds ratio, CI: confidence interval,
**
= highly significant.
Luminal A (ER+/PR+/HER2-); HER2Neu: Human epidermal growth factor2, ER: Estrogen Receptor, PR: Progesterone Receptor.